Dr Ronan MacLoughlin, PhD, MBS is currently Director of R&D, Science and Emerging Technologies in Aerogen Limited. Dr MacLoughlin has more than 20 years’ experience in Respiratory Drug Delivery with several nebuliser, and accessory product launches over that time. He has responsibility for new product development, establishing and exploiting the science underpinning respiratory drug delivery and identifying new and potentially disruptive emerging technologies. To this end, he has developed multiple technologies and products with several patents granted and pending, that cover the range of drug, device, drug/device combination products, patient interventions, and patient interfaces. Of note, this includes the world’s first fit for purpose mass vaccination by inhalation delivery system, currently in use with Convidicia Air, the first approved inhaled COVID-19 vaccine. Dr MacLoughlin was also previously head of Medical Affairs in Aerogen.

Dr MacLoughlin currently serves on (previously chair) the Industry Representative Group in CURAM, the Science Foundation Ireland center for the development
the next generation of smart medical devices, and sits on the board, (previously chair) of the Medical and Engineering Technologies Center (MET), the Enterprise Ireland Technology Gateway.
Additionally, he is currently chair of the Paediatric and Cystic Fibrosis working group within the International Society for Aerosols
in Medicine (ISAM). He sits on the board of LEP Biomedical, a preclinical company focused on the development of novel implantable drug delivery
systems for the treatment of glaucoma and other ophthalmic conditions.

Finally, Dr MacLoughlin holds the position of adjunct Associate Professor in Trinity College Dublin (School of Pharmacy and Pharmaceutical Sciences), and
Senior Honorary lecturer in the Royal College of Surgeons, Ireland (School of Pharmacy & Biomolecular Sciences).